Literature DB >> 22009695

Is sarcosine a biomarker for prostate cancer?

Haleem J Issaq1, Timothy D Veenstra.   

Abstract

Sarcosine was suggested in a letter to Nature in 2009 as a biomarker for prostate cancer. This communication reviews what has been accomplished to date to determine whether sarcosine is or is not a biomarker for prostate cancer that can replace prostate-specific antigen tests.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22009695     DOI： 10.1002/jssc.201100572

Source DB:  PubMed          Journal:  J Sep Sci        ISSN： 1615-9306            Impact factor:   3.645


  10 in total

1.  Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Stella Koutros; Tamra E Meyer; Stephen D Fox; Haleem J Issaq; Timothy D Veenstra; Wen-Yi Huang; Kai Yu; Demetrius Albanes; Lisa W Chu; Gerald Andriole; Robert N Hoover; Ann W Hsing; Sonja I Berndt
Journal:  Carcinogenesis       Date:  2013-05-22       Impact factor: 4.944

2.  Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery.

Authors:  Tong Zhang; David G Watson; Lijie Wang; Muhammad Abbas; Laura Murdoch; Lisa Bashford; Imran Ahmad; Nga-Yee Lam; Anthony C F Ng; Hing Y Leung
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

Review 3.  A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential.

Authors:  Jaspreet Singh Batra; Swati Girdhani; Lynn Hlatky
Journal:  J Biomark       Date:  2014-03-12

Review 4.  Sarcosine as a potential prostate cancer biomarker--a review.

Authors:  Natalia Cernei; Zbynek Heger; Jaromir Gumulec; Ondrej Zitka; Michal Masarik; Petr Babula; Tomas Eckschlager; Marie Stiborova; Rene Kizek; Vojtech Adam
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

5.  Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.

Authors:  Clara Pérez-Rambla; Leonor Puchades-Carrasco; María García-Flores; José Rubio-Briones; José Antonio López-Guerrero; Antonio Pineda-Lucena
Journal:  Metabolomics       Date:  2017-03-09       Impact factor: 4.290

Review 6.  Approaches to urinary detection of prostate cancer.

Authors:  Jillian N Eskra; Daniel Rabizadeh; Christian P Pavlovich; William J Catalona; Jun Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-01-17       Impact factor: 5.554

Review 7.  The human flavoproteome.

Authors:  Wolf-Dieter Lienhart; Venugopal Gudipati; Peter Macheroux
Journal:  Arch Biochem Biophys       Date:  2013-03-15       Impact factor: 4.013

8.  Metabolomics and its Application to the Development of Clinical Laboratory Tests for Prostate Cancer.

Authors:  Jonathan E McDunn; Steven M Stirdivant; Lisa A Ford; Robert L Wolfert
Journal:  EJIFCC       Date:  2015-03-10

Review 9.  Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.

Authors:  Ana Rita Lima; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Transl Oncol       Date:  2016-08       Impact factor: 4.243

10.  Programming bulk enzyme heterojunctions for biosensor development with tetrahedral DNA framework.

Authors:  Ping Song; Juwen Shen; Dekai Ye; Baijun Dong; Fei Wang; Hao Pei; Jianbang Wang; Jiye Shi; Lihua Wang; Wei Xue; Yiran Huang; Gang Huang; Xiaolei Zuo; Chunhai Fan
Journal:  Nat Commun       Date:  2020-02-11       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.